| Filed On | Filing |
|---|---|
| 12 May 2026 |
8-K/A: Results of Operations and Financial Condition
London, May 12, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026... |
Loading...
